TU2218 + pembrolizumab

TU2218 + pembrolizumab is a combination therapy under clinical investigation for advanced solid tumors. TU2218 is a novel, orally available small molecule that acts as a dual inhibitor of transforming growth factor beta receptor 1 (TGFβ-RI/ALK5) and vascular endothelial growth factor receptor 2 (VEGFR2). By targeting both the TGFβ and VEGF pathways, which are known to contribute to an immunosuppressive tumor microenvironment, TU2218 aims to enhance the efficacy of immune checkpoint inhibitors such as pembrolizumab. Pembrolizumab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) pathway, thereby promoting anti-tumor immune responses. The combination seeks to overcome resistance mechanisms in cancer immunotherapy by simultaneously inhibiting key signaling pathways involved in tumor progression and immune evasion. Clinical trials have focused on patients with advanced solid tumors, including head and neck squamous cell carcinoma, biliary tract cancer, colorectal cancer, and other malignancies[1][4][5][6][8].

Brand names

Keytruda

Other names

TU2218 + Keytruda